Evidence map›Paper›PMID 19997598›Full record

ArticlePloS one2009

Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation.

Derek M Murphy, Patrick G Buckley, Kenneth Bryan, Sudipto Das, Leah Alcock, Niamh H Foley, Suzanne Prenter, Isabella Bray, Karen M Watters, Desmond Higgins and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 84 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Catastrophic ATP loss underlies a metabolic combination therapy tailored forProceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Derek M MurphyDepartment of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland.
Patrick G Buckley
Kenneth Bryan
Sudipto Das
Leah Alcock
Niamh H Foley
Suzanne Prenter
Isabella Bray
Karen M Watters
Desmond Higgins
Raymond L Stallings
National Children’s Research Centre · IERoyal College of Surgeons in Ireland · IEUniversity College Dublin · IE

Funding

MiRNA Expression in NeuroblastomaR01CA127496 · NCI · ROYAL COLLEGE OF SURGEONS IN IRELAND · PI STALLINGS, RAYMOND LOUIS · 2008 to 2012
$976k
NCI NIH HHS 5R01CA127496NCI NIH HHS R01 CA127496
6 · The paper itself

Abstract

backgroundNeuroblastoma, a cancer derived from precursor cells of the sympathetic nervous system, is a major cause of childhood cancer related deaths. The single most important prognostic indicator of poor clinical outcome in this disease is genomic amplification of MYCN, a member of a family of oncogenic transcription factors. METHODOLOGY: We applied MYCN chromatin immunoprecipitation to microarrays (ChIP-chip) using MYCN amplified/non-amplified cell lines as well as a conditional knockdown cell line to determine the distribution of MYCN binding sites within all annotated promoter regions.

conclusionAssessment of E-box usage within consistently positive MYCN binding sites revealed a predominance for the CATGTG motif (p<0.0016), with significant enrichment of additional motifs CATTTG, CATCTG, CAACTG in the MYCN amplified state. For cell lines over-expressing MYCN, gene ontology analysis revealed enrichment for the binding of MYCN at promoter regions of numerous molecular functional groups including DNA helicases and mRNA transcriptional regulation. In order to evaluate MYCN binding with respect to other genomic features, we determined the methylation status of all annotated CpG islands and promoter sequences using methylated DNA immunoprecipitation (MeDIP). The integration of MYCN ChIP-chip and MeDIP data revealed a highly significant positive correlation between MYCN binding and DNA hypermethylation. This association was also detected in regions of hemizygous loss, indicating that the observed association occurs on the same homologue. In summary, these findings suggest that MYCN binding occurs more commonly at CATGTG as opposed to the classic CACGTG E-box motif, and that disease associated over expression of MYCN leads to aberrant binding to additional weaker affinity E-box motifs in neuroblastoma. The co-localization of MYCN binding and DNA hypermethylation further supports the dual role of MYCN, namely that of a classical transcription factor affecting the activity of individual genes, and that of a mediator of global chromatin structure.

Indexed as

Binding SitesCell Line, TumorChromatin ImmunoprecipitationDNA, IntergenicDNA MethylationE-Box ElementsGenetic LociHumansMicroRNAsNeuroblastomaN-Myc Proto-Oncogene ProteinNuclear ProteinsOncogene ProteinsPromoter Regions, GeneticProtein BindingTranscription FactorsDNA, IntergenicMicroRNAsMIRN135 microRNA, humanMYCN protein, humanN-Myc Proto-Oncogene ProteinNuclear ProteinsOncogene ProteinsTranscription Factors

Identifiers

PMID19997598
PMCPMC2781550
OpenAlexW2104784323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.